Illumina news

The article highlights Illumina's strategic AI initiatives and potential to create a new growth engine through its sequencing technology and biological data capabilities. The focus on expanding partnerships and improving core business suggests optimistic prospects for future stock performance over a 5-year horizon.

ILMN has a lower Zacks Rank #2 (Buy), significantly higher forward P/E of 50.77, higher PEG ratio of 3.85, higher P/B ratio of 14.47, and a Value grade of D, indicating less attractive valuation metrics for value investors.

Recognized as a well-known integrator of robotics in the medical sector, partnering with Hamilton Robotics for automation solutions.

Company raised full-year 2026 revenue and EPS guidance, achieved 9.5% YoY revenue growth, demonstrated strong oncology portfolio momentum, expanded multiomics capabilities, and maintains manageable leverage with sufficient liquidity. Stock has surged 129.6% over the past year and holds a Zacks Rank #2 (Buy) rating.

Mentioned only as a compatible integration partner for Metafoodx's platform via open API. No specific performance or business impact information provided.

Critical position in oncology ecosystem as genomic tools provider; expanded Billion Cell Atlas program and launched whole-genome sequencing solution for minimal residual disease research.

Key player in the market with strong growth prospects; advances in sequencing platforms mentioned as a driver of market expansion, directly benefiting sequencing technology providers.

ILMN holds Zacks Rank #2 (Buy) with exceptional 194.6% share price rally over the past year, consistent earnings beats averaging 9.7%, though long-term growth rate of 13% lags industry average.

Identified as a leading competitor with recent product innovation (February 2025 release of 5-base methylation analysis kits), positioned to capitalize on growing demand for sequencing technologies and epigenetic analysis.

Outstanding share price performance (+194.6% YoY), consistent earnings beats (9.7% average surprise), and Zacks Rank #2 (Buy) rating. However, long-term earnings growth estimate (13%) lags industry average (23%), which moderates the sentiment slightly.

Beat expectations with 9.5% YoY revenue growth and raised full-year guidance to $4.60-4.64B, but shares traded lower the following day despite positive results, indicating mixed market sentiment despite strong fundamentals.

Illumina gained only 2% over the past month, modestly outperforming broader market. While revenues grew 9.4% year-over-year and EPS improved, the company maintains a Hold rating with modest estimate revisions of 1.9%, indicating stable but unexceptional performance.

Zacks Rank #2 with consistent earnings beats (9.7% average surprise), exceptional 194.6% share price rally over past year, though long-term earnings growth of 13% trails industry average of 23%.

Rated Zacks Rank #2 (Buy) with consistent earnings beats (9.7% average surprise) and exceptional share performance of 194.6% over the past year, significantly outpacing industry growth.

Zacks Rank #2, exceptional share performance (+194.6% YoY), consistent earnings beats (9.7% average surprise), and strong long-term growth rate of 13%.

Zacks Rank #2 with exceptional share performance rallying 194.6% compared to industry's 24.6% growth, consistent earnings beats (9.7% average surprise), though long-term earnings growth rate of 13% lags industry's 23%.

Listed among precision medicine companies featured in the report, indicating market presence and partnership activity, but no specific positive or negative developments are mentioned.

Committed $1.2 billion in R&D investment in 2024, signaling active positioning for AI-integrated future and strong commitment to maintaining competitive advantage in genomics infrastructure.

Mentioned as the parent company that spun off Grail in 2024. No specific performance data or analysis provided in the article regarding Illumina itself.

Identified as a leading market player with presence in blood transfusion diagnostics solutions, benefiting from the growing market expansion and technological innovations in molecular diagnostics.

Key player in cancer biomarkers market with strong positioning in genomics and omics technologies, which are expected to record the highest CAGR during the forecast period.

Included in the featured companies list for bioinformatics collaboration, suggesting market presence and partnership activity, but no specific deal details or performance metrics are provided.

Key company in the market benefiting from technological advancements in sequencing tools and data analysis capabilities driving eDNA market expansion.

Listed as a leading player and highlighted for recent product innovation with MiSeq i100 and MiSeq i100 Plus sequencing systems launched in 2024.

Listed as a leading market player in spatial genomics and transcriptomics, benefiting from growing demand for advanced sequencing technology and precision medicine applications.